Evidence map›Paper›PMID 35386737›Full record

ArticleJournal of scleroderma and related disorders2021

Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: An observational study.

Johan Clukers, Maarten Lanclus, Dennis Belmans, Cedric Van Holsbeke, Wilfried De Backer, Dharshan Vummidi, Paul Cronin, Ben R Lavon, Jan De Backer, Dinesh Khanna

Open access · greenAbstract read
In one paragraph

Article in Journal of scleroderma and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. A systematic review of the role of quantitative CT in the prognostication and disease monitoring of interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Johan ClukersFaculty of medicine and health sciences, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0003-0021-8870
Maarten LanclusFLUIDDA Inc, Los Angeles, CA, USA.
Dennis BelmansFLUIDDA NV, Kontich, Belgium.
Cedric Van HolsbekeFLUIDDA NV, Kontich, Belgium.ORCID https://orcid.org/0000-0003-0248-841X
Wilfried De BackerFaculty of medicine and health sciences, University of Antwerp, Antwerp, Belgium.
Dharshan VummidiDivision of Radiology, University of Michigan, Ann Arbor, MI, USA.
Paul CroninDivision of Radiology, University of Michigan, Ann Arbor, MI, USA.
Ben R LavonFLUIDDA NV, Kontich, Belgium.
Jan De BackerFLUIDDA Inc, Los Angeles, CA, USA.
Dinesh KhannaDivision of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, Ann Arbor, MI, USA.
Fluidda (Belgium) · BEUniversity of Michigan · USFluidda (United States) · USUniversity of Antwerp · BE

Funding

Outcomes Research in Rheumatic DiseasesK24AR063120 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2012 to 2022
$1.6M
Systemic Sclerosis-Associated Interstitial Lung Disease Response IndexR01AR070470 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2017 to 2019
$642k
NIAMS NIH HHS K24 AR063120NIAMS NIH HHS R01 AR070470
6 · The paper itself

Abstract

Introduction: Systemic sclerosis-associated interstitial lung disease accounts for up to 20% of mortality in these patients and has a highly variable prognosis. Functional respiratory imaging, a quantitative computed tomography imaging technique which allows mapping of regional information, can provide a detailed view of lung structures. It thereby shows potential to better characterize this disease. Purpose: To evaluate the use of functional respiratory imaging quantitative computed tomography in systemic sclerosis-associated interstitial lung disease staging, as well as the relationship between short-term changes in pulmonary function tests and functional respiratory imaging quantitative computed tomography with respect to disease severity. Materials and methods: An observational cohort of 35 patients with systemic sclerosis was retrospectively studied by comparing serial pulmonary function tests and in- and expiratory high-resolution computed tomography over 1.5-year interval. After classification into moderate to severe lung disease and limited lung disease (using a hybrid method integrating quantitative computed tomography and pulmonary function tests), post hoc analysis was performed using mixed-effects models and estimated marginal means in terms of functional respiratory imaging parameters. Results: At follow-up, relative mean forced vital capacity percentage change was not significantly different in the limited (6.37%; Conclusion: Functional respiratory imaging is able to differentiate moderate to severe disease versus limited disease and to detect disease progression in systemic sclerosis.

Indexed as

computer-assisted image analysisInterstitial lung diseasemultidetector-row computed tomographysystemic scleroderma

Identifiers

PMID35386737
PMCPMC8892932
OpenAlexW3123827282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.